Complement receptor type two (CR2,CR21). A target for influencing the humoral immune response and antigen-trapping

Immunologic Research

Volumn 20, Issue 3, 1999, Pages 187-194

  Prodinger, Wolfgang M ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

C3; CD21; Complement; EBV; Immunity; Receptor; Structure; Therapy

Indexed keywords

ANTIGEN; CD23 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR;

ANIMAL EXPERIMENT; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033499991     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02790402     Document Type: Review

References (52)

1. 1 Fearon DT, Carter RH: The CD19/ CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity Annu Rev Immunol 1995;13:127-149.
2. 2 Doody GM, Dempsey PW, Fearon DT: Activation of B lymphocytes: Integrating signals from CD19, CD22 and Fc gamma RIIb1 Curr Opin Immunol 1996;8:378-382.
3. 3 Carroll MC: The role of complement and complement receptors in induction and regulation of immunity Annu Rev Immunol 1998;16: 545-568.
4. 4 Tedder TF, Clement LT, Cooper MD: Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody J Immunol 1984;133: 678-683.
5. 5 Reynes M, Aubert JP, Cohen JH, et al.: Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens J Immunol 1985;135:2687-2694.
6. 6 Sixbey JW, Davis DS, Young LS, Hutt-Fletcher LM, Tedder TF, Rickinson AB: Human epithelial cell expression of an Epstein-Barr virus receptor J Gen Virol 1987; 68:805-811.
7. 7 Reid KBM, Bentley PI, Campell RD, et al.: Complement system proteins which interact with C3b or C4b Immunol Today 1986;7: 230-234.
8. 8 Norman DG, Barlow PN, Baron M, Day AJ, Sim RB, Campbell ID: Three-dimensional structure of a complement control protein module in solution J Mol Biol 1991; 219:717-725.
9. 9 Weis JJ, Toothaker LE, Smith JA, Weis JH, Fearon DT: Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins J Exp Med 1988;167: 1047-1066.
10. 10 Moore MD, Cooper NR, Tack BF, Nemerow GR: Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type two) of human B lymphocytes Proc Natl Acad Sci U S A 1987;84: 9194-9198.
11. 11 Liu YJ, Xu JC, Debouteiller O, et al.: Follicular dendritic cells specifically express the long CR2/ CD21 isoform J Exp Med 1997; 185:165-170.
12. 12 Ahearn JM, Fearon DT: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21) Adv Immunol 1989;46: 183-219.
13. 13 Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT: Functional dissection of the CD21/CD19TAPA-1/ Leu-13 complex of B lymphocytes J Exp Med 1993;178:1407-1417.
14. 14 Hebell T, Ahearn JM, Fearon DT: Suppression of the immune response by a soluble complement receptor of B lymphocytes Science 1991;254:102-105.
15. 15 Fang Y, Xu C, Fu YX, Holers VM, Molina H: Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response J Immunol 1998;160:5273-5279.
16. 16 Schwendinger MG, Spruth M, Schoch J, Dierich MP, Prodinger WM: A novel mechanism of alternative pathway complement activation accounts for the deposition of C3-fragments on CR2-expressing homologous cells J Immunol 1997;158:5455-5464.
17. 17 Heath SL, Tew JG, Szakal AK, Burton GF: Follicular dendritic cells and human immunodeficiency virus infectivity [see comments] Nature 1995;377:740-744.
18. 18 Barlow PN, Steinkasserer A, Norman DG, et al: Solution structure of a pair of complement modules by nuclear magnetic resonance J Mol Biol 1993;232:268-284.
19. 19 Rao PE, Wright SD, Westberg EF, Goldstein G: OKB7, a monoclonal antibody that reacts at or near the C3d binding site of human CR2 Cell Immunol 1985;93: 549-555.
20. 20 Nemerow GR, Wolfert R, McNaughton ME, Cooper NR: Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) J Virol 1985;55:347-351.
21. 21 Prodinger WM, Schwendinger MG, Schoch J, Köchle M, Larcher C, Dierich MP: Characterization of C3dg Binding to a Recess Formed between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21) J Immunol 1998;161:4604-4610.
22. 22 Prodinger WM, Schoch J, Schwendinger MG, et al.: Expression in insect cells of the functional domain of CD21 (complement receptor type two) as a truncated soluble molecule using a baculovirus vector Immunopharmacology 1997;38:141-148.
23. 23 Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM: Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3 An initial model of ligand interaction with two linked short consensus repeat modules J Immunol 1995; 154:5426-5435.
24. 24 Martin DR, Yuryev A, Kalli KR, Fearon DT, Ahearn JM: Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2 J Exp Med 1991;174: 1299-1311.
25. 25 Molina H, Brenner C, Jacobi S, et al.: Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides At least two distinct sites are necessary for ligand-receptor interaction J Biol Chem 1991;266: 12173-12179.
26. 26 Moore MD, DiScipio RG, Cooper NR, Nemerow GR: Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2) J Biol Chem 1989;264: 20576-20582.
27. 27 Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM: X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2 Science 1998;280:1277-1281.
28. 28 Lambris JD, Ganu VS, Hirani S, Müller-Eberhard HJ: Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement Proc Natl Acad Sci U S A 1985;82:4235-4239.
29. 29 Hull-Fletcher LM, Fowler E, Lambris JD, Feighny RJ, Simmons JG, Ross GD: Studies of the Epstein Barr virus receptor found on Raji cells II A comparison of lymphocyte binding sites for Epstein Barr virus and C3d J Immunol 1983; 130:1309-1312.
30. 30 Nemerow GR, Mold C, Schwend VK,Tollefson V, Cooper NR: Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr viras (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d J Virol 1987;61:1416-1420.
31. 31 Tanner J, Weis J, Fearon D, Whang Y, Kieff E: Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis Cell 1987;50:203-213.
32. 32 Li Q, Spriggs MK, Kovats S, et al.: Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes J Virol 1997;71: 4657-1662.
33. 33 Bonnefoy JY, Lecoanet Henchoz S, Aubry JP, Gauchat JF, Graber P: CD23 and B-cell activation Curr Opin Immunol 1995;7:355-359.
34. 34 Aubry JP, Pochon S, Gauchat JF, et al.: CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21 J Immunol 1994;152:5806-5813.
35. 35 Lowe J, Brown B, Hardie D, Richardson P, Ling N: Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia Immunol Lett 1989; 20:103-109.
36. 36 Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N: Determination of soluble CD21 as a parameter of B cell activation [see comments] Clin exp Immunol 1993;93:195-199.
37. 37 Larcher C, Fend F, Mitterer M, Prang N, Schwarzmann F, Huemer HP: Role of Epstein-Barr virus and soluble CD21 in persistent polyclonal B-cell lymphocytosis Br J Haematol 1995;90:532-540.
38. 38 Fremeaux Bacchi V, Bernard I, Maillet F, et al.: Human lymphocyte shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23 Eur J Immunol 1996;26: 1497-1503.
39. 39 Moore MD, Cannon MJ, Sewall A, Finlayson M, Okimoto M, Nemerow GR: Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats J Virol 1991;65:3559-3565.
40. 40 Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM: A molecular and immunochemical characterization of mouse CR2 Evidence for a single gene model of mouse complement receptors 1 and 2 J Immunol 1990;145:2974-2983.
41. 41 Heyman B, Wiersma EJ, Kinoshita T: In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody J Exp Med 1990; 172:665-668.
42. 42 Gustavsson S, Kinoshita T, Heyman B: Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction J Immunol 1995;154: 6524-6528.
43. 43 Ahearn JM, Fischer MB, Croix D, et al.: Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen Immunity 1996;4:251-262.
44. 44 Molina H, Holers VM, Li B, et al.: Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 Proc Natl Acad Sci U S A 1996;93: 3357-3361.
45. 45 Tedder TF, Inaoki M, Sato S: The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity Immunity 1997; 6:107-118.
46. 46 Moghaddam A, Koch J, Annis B, Wang F: Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus J Virol 1998;72:3205-3212.
47. 47 Makrides SC: Therapeutic inhibition of the complement system Pharmacol Rev 1998;50:59-87.
48. 48 Weisman HF, Barlow T, Leppo MK, et al.: Soluble human complement receptor type I: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis Science 1990;249:146-151.
49. 49 Kalli KR, Hsu P, Fearon DT: Therapeutic uses of recombinant complement protein inhibitors Springer Semin Immunopathol 1994;15: 417-431.
50. 50 Gu SY, Huang TM, Ruan L, et al: First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen Dev Biol Stand 1995; 84:171-177.
51. 51 Hoffman GJ, Lazarowitz SG, Hayward SD: Monoclonal antibody against a 250,000-dalton glycoprotein of a Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen Proc Natl Acad Sci U S A 1980;77:2979-2983.
52. 52 Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT: C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996;271:348-350.